Efficacy gap between phase II and subsequent phase III studies in oncology

AIMS: There is a trend for more flexibility in timing of evidence generation in relation to marketing authorization, including the option to complete phase III trials after authorization or not at all. This paper investigated the relation between phase II and III clinical trial efficacy in oncology....

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Clin Pharmacol
Autori principali: Vreman, Rick A., Belitser, Svetlana V., Mota, Ana T.M., Hövels, Anke M., Goettsch, Wim G., Roes, Kit C.B., Leufkens, Hubert G.M., Mantel‐Teeuwisse, Aukje K.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2020
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7318994/
https://ncbi.nlm.nih.gov/pubmed/32034790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14237
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi